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Abstract
Local allergic rhinitis (LAR) is a novel concept defining clinical allergic rhinitis 
with no evidence of systemic sensitization to aeroallergens. In this unique condi-
tion, the allergic response is confined to the nasal mucosa and can be demon-
strated using different methods such as the immunoglobulin-E (IgE) level in the 
nasal secretions, nasal provocation test (NPT), or basophil activation test (BAT) 
with specific allergens or more sophisticated molecular diagnostic techniques. 
Furthermore, local allergic rhinitis can be relieved by interventions used to treat 
systemic allergic conditions such as antihistamines or anti-IgE monoclonal antibod-
ies. Last but not least, several small studies demonstrated the efficacy of allergen 
immunotherapy for ameliorating LAR symptoms. In this chapter we reviewed old 
data and new concepts regarding clinical manifestation, plausible mechanisms, and 
treatments of LAR. The long-standing question whether LAR is an integral part of 
the “atopic spectrum” or it is a single-organ immune-mediated disease, is yet to be 
determined.
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1. Definition of local allergic rhinitis
Local allergic rhinitis (LAR) is defined by symptoms suggestive of allergic 
rhinitis (AR), but with no detected sensitivity to an allergen using common allergy 
testing, while allergen-specific immunoglobulin-E (IgE) in the nasal mucosa can be 
detected.
2. Background
The first report of local production of IgE in the nasal mucosa was documented 
in 1975 among patients with typical symptoms of allergic rhinitis and negative 
allergy evaluation (i.e., negative skin prick tests (SPT) or serum-specific IgE 
(sIgE)). In this early report, specific IgE antibodies to Dermatophagoides pteronys-
sinus (house dust mite) had been detected in the nasal secretions of patients [1]. 
Later on, several methods to detect IgE in nasal secretions were evaluated, but 
only in 1989 a direct measuring technique was established [2]. This was tracked in 
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2010, by defining the concept entopy as opposed to atopy. Although still somewhat 
controversial, entopy addresses local production of IgE in the nasal and respira-
tory mucosa, while atopy is characterized by serum-specific IgE and positive skin 
reaction [3, 4]. In recent years advances in documentation of nasal IgE production 
among patients with typical symptoms of allergic rhinitis substantiated the entity 
of LAR, which is now accepted and relevant worldwide.
3. Prevalence
The prevalence of LAR is uncertain and was long considered a rare disorder. 
In recent years, with the improvement of diagnostic methods, new and surprising 
data has emerged. In 2012 Rondon et al. reported a prevalence of 25.7% of LAR 
among a group of 428 adult patients with chronic rhinitis. In the same cohort, 63.1% 
were diagnosed with AR and 11.2% with non-allergic rhinitis (NAR). The most 
frequently causative allergen in both LAR and AR was D. pteronyssinus (house dust 
mite) [4]. Similar ratio between LAR and AR was reported by Bozek et al. among 
219 elderly patients (mean age 65.8 years). The prevalence of LAR was 21% and 
that of AR was 40.2%, and again D. pteronyssinus was found to be the major culprit 
allergen [5]. However, this data was obtained in selected populations of patients 
with chronic rhinitis, while the prevalence of LAR in the general population is yet to 
be established.
4. Diagnosis of LAR
As mentioned above, LAR has to be considered in the differential diagnosis of 
AR, when no evidence of systemic atopy is present. The evaluation of a patient 
suspected to have LAR should include a detailed clinical history, typically resem-
bling AR, as well as assessment of comorbidities, such as ocular, skin, and bronchial 
symptoms. This may enable further evaluation for systemic atopy or a filter for 
patients with non-allergic rhinitis (NAR; see Table 1). A detailed physical exami-
nation includes inspection of the nasal cavity via nasal endoscopy, and for some 
patients, a CT scan may be required to exclude other causes of chronic rhinitis. 
This should be followed by tests to verify sensitization to aeroallergens, either skin 
prick tests (SPT) or serum-specific IgE. It has been suggested that when there is a 
high index of suspicion of allergy and no reaction to SPT, intradermal skin tests to 
common aeroallergens may be considered. In the absence of evidence for systemic 
sensitization, one must prove local rhino-mucosa hyper-reactivity to aeroallergens 
in order to diagnose LAR [6, 7] (Figure 1). Three methods can be used to diagnose 
LAR:
1. Nasal allergen provocation test (NAPT) is considered the gold standard for LAR 
diagnosis. NAPT consists of eliciting a local nasal allergic response by expo-
sure to allergens. A response is characterized by rhinorrhea, itching, sneez-
ing, edema of the nasal mucosa, and increased airflow resistance following 
exposure of the nasal mucosa to a specific allergen. NAPT has the potential to 
differentiate between allergic (both AR and LAR) and the non-allergic rhinitis 
(NAR) or healthy controls. Furthermore, among allergic patients it could dif-
ferentiate between clinically relevant and nonrelevant allergen sensitizations. 
NAPT could be done with single allergen or with multiple aeroallergens in one 
session [8]. In another study 60% of LAR patients responded immediately to 
nasal allergen provocation test (NAPT) with a specific allergen demonstrating 
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nasal symptoms, elevated tryptase (mast cell activation marker), and eosino-
phil cationic protein (ECP marker of eosinophil activation) [9, 10]. Notably, 
this method may highlight a subgroup of patients that suffers from both local 
and systemic sensitizations, namely, the “dual allergic rhinitis (DAR)” patient. 
For instance, a DAR patient may suffer from perennial symptoms, but his 
allergy testing will demonstrate sensitivity only to seasonal allergens, whereas 
his NAPT study will be positive to perennial allergens.
NAPT is a sensitive and specific technique, although it requires special training and 
is time-consuming [8]. Furthermore, it has some pitfalls. Nasal challenge with saline 
prior to NAPT is recommended to rule out non-specific nasal hyper-reactivity, which 
may induce a false-positive result. Having said that, there is yet lack of standardization 
regarding allergenic extract, dose, timing, and outcome definitions of NAPT [9].
2. sIgE in the nasal secretions is determined in nasal lavage fluid (e.g., after natural 
exposure), after NAPT, or following mucosal brushing [10]. Notably, sIgE could 
also be measured in nasal biopsies for more accurate results, but in the clinical 
practice, noninvasive methods might be preferable. The measurement of sIgE 
in nasal secretions is dependent on the technique used. Thus, although positive 
results are highly specific (>90%), sensitivity is rather low utilizing nasal lavage, 
ranging from 22 to 40%, most likely owing to dilution effect [7, 9]. Hence, when 
the lavage results are negative and there is a high index of suspicion, it is recom-
mended to perform a more invasive procedure, as specified earlier.
3. Basophil activation test (BAT): Peripheral basophils are key cells in allergic 
responses and are involved in immediate IgE-mediated reactions. Their 
primary role is to degranulate pro-inflammatory mediators following stimula-
tion and activation by allergens. Basophil activation can be measured by flow 
• Chronic rhinosinusitis
 ○ With nasal polyposis (CRSWNP)




 ○ Related to systemic diseases:
1. Genetic disease: cystic fibrosis, primary ciliary dyskinesia
2. Autoimmune/inflammatory diseases: granulomatosis, relapsing polychondritis, sarcoidosis
3. Amyloidosis
4. Malignancy related
 ○ Atrophic rhinitis
 ○ Occupational rhinitis (irritant)
 ○ Rhinitis medicamentosa
 ○ Anatomic defects:
1. Local: Septal deviation, turbinate hypertrophy, adenoid hypertrophy (nonatopic variant)
2. Nonlocal: Cerebrospinal fluid leaking
Table 1. 
Differential diagnosis of allergic and local allergic rhinitis.
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cytometry in which surface activation markers such as CD63 are quantified. 
The BAT is a flow cytometry-based assay performed on patient’s peripheral 
blood, where the expression of these activation markers is measured following 
stimulation with allergen. BAT have been extensively studied and validated for 
in vitro diagnosis of sensitization to inhalant and food allergens, Hymenoptera 
venom, and several drug hypersensitivities [11]. The first evidence of specific 
basophil activation in peripheral blood from patients with LAR was reported 
in 2013 by Gome et al. [12], in which it was demonstrated for the first time that 
the activation of basophils in LAR patients was mediated by specific IgE to D. 
pteronyssinus. BAT was linked with 50% sensitivity and >90% specificity, which 
may be superior to the current data on sIgE in nasal lavage (e.g., specificity of 
22%). In another study of patients with LAR to Olea europaea, BAT sensitivity 
was 66% with >90% specificity [7].
In summary, BAT has a medium-grade sensitivity and a high specific-
ity for the diagnosis of local sIgE, which may outperform other methods for 
sIgE detection. It is less time-consuming; however, it is performer dependent 
compared to NAPT.
5. The pathophysiology of LAR
The pathogenesis of allergic rhinitis (AR) is well established. It is a Th2-
mediated disease which involves mast cell activation, recruitment of eosinophils, 
basophils and T cells expressing Th2 cytokines, and secretion of interleukin as 
Figure 1. 
Allergic rhinitis diagnostic algorithm. SPT, skin prick test; ID, intradermal skin tests; sIgE, specific IgE; NAPT, 
nasal provocation test; BAT, basophil activation test.
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IL-4, IL-13, IL-5, and others. The pathophysiology of LAR is less well established, 
and the question why the majority of allergic patients exhibit systemic sensi-
tization (atopy) while some develop only local responses (entopy) is yet to be 
answered. Nonetheless, it has been suggested that the natural history of allergy 
is composed of multiple steps leading eventually to atopy. In a recent review, 
Dullaers et al. [13] suggested that the first step to atopy takes place in the nasal 
mucosa, where allergen-specific IgE is produced. The authors further hypothe-
sized that some subjects lack spillover of these mucosal-produced allergen-specific 
IgEs into the circulation. In another study, the detection of allergen-specific IgE on 
the surfaces of peripheral basophils from patients with LAR eluded to the idea that 
the second step to atopy is on the surface of peripheral basophils and other target 
immune cells, followed by the third and final step which is the detection of serum-
specific IgE and skin mast cell sensitization [12]. Thus, differences between LAR 
and AR may explain different stages of sensitization to allergen. For example, it 
was demonstrated that following nasal provocation of patients allergic to olive, the 
ECP levels in nasal lavage were significantly higher in both AR and LAR patients 
than in controls, while basophil activation test (BAT) was higher only in the LAR 
group, which potentially represents an earlier step in sensitization, associated 
more closely with LAR [14].
In contrast, similarities between AR and LAR pathophysiology were observed 
while evaluating the immunologic responses to therapy and particularly to immu-
notherapy. Namely, alike AR patients a significant increase of serum-specific IgG4 
antibodies is observed following allergen immunotherapy among LAR patients. 
This not only substantiates the IgE-mediated mechanism of disease but also the 
notion that LAR may be the prodrome of AR [15]. Last but not least, allergen-
specific IgEs to various allergens in the nasal scrapings from patients with AR, 
non-allergic rhinitis (NAR), and healthy controls were reported to be 86.7, 33.3, 
and 50%, respectively. Thus, although a wide difference between allergic and 
non-allergic patients was documented, a relatively high percent of IgE production 
was observed among controls [16]. One may suggest that healthy controls were 
sensitized but developed spontaneous tolerance, e.g., “a backward step” following 
the first, second, or third stage of atopy.
6. Local allergic rhinitis and comorbidity
AR is an essential part of the “atopic march” [17] and thereby associated with 
comorbidities, such as asthma, atopic dermatitis, food allergies eosinophilic 
esophagitis, allergic conjunctivitis, chronic rhinosinusitis with nasal polyposis 
(CRSwNP), and more [18]. The association of these comorbidities with local 
allergic rhinitis (LAR) was less explored [19], although bronchial symptoms have 
been reported in patients with LAR [20] and any chronic rhinitis is a risk factor for 
poorly controlled asthma with recurrent hospital visits [19]. Recently, self-reported 
bronchial symptoms, suggestive of asthma, were reported in over 30% of patients 
with LAR, suggesting a new asthma phenotype, “local allergic asthma” [21, 22]. 
As in classical allergic rhinitis, conjunctival symptoms were also associated with 
LAR. It was shown that patients with LAR experience ocular symptoms during 
nasal exacerbations due to allergen exposure or during in vitro nasal provocation 
tests [20]. In one study, this was the most prevalent comorbidity associated with 
LAR [23]. In a recent study by Rondon et al. [19], a 10-year follow-up of 176 LAR 
patients entailed other comorbidities, such as food allergy and drug hypersensitiv-
ity, which were documented only in few patients.
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7. Treatment of LAR
In daily practice NAPT, BAT, or other specific tests are rarely performed. Hence, 
performing a therapeutic trial with antihistamines may be beneficial for diagnosis 
of LAR. Early and substantial response to antihistamine further supports an allergic 
histamine-driven mechanism. In the same line of thought, treatment with nasal 
corticosteroid spray may be clinically beneficial, but will not enable to differentiate 
causes of chronic rhinitis. Most LAR patients are currently treated similarly to AR 
patients, and according to the allergic rhinitis and its impact on asthma (ARIA) 
guidelines. This is done by using personal and environmental education, allergen 
avoidance measures and non-specific pharmacologic modalities, such as, intranasal 
corticosteroids, and oral and intranasal antihistamines [7–10]. Having said that, 
such non-specific therapy for LAR will ameliorate symptoms but alike AR will not 
change the natural progression of disease.
Immunotherapy is a common therapeutic modality for moderate to severe 
unresponsive AR. Allergen immunotherapy is based on gradual exposure to a 
culprit allergen via subcutaneous or sublingual exposure. This will eventually result 
in “induced tolerance” to the targeted allergen and amelioration of the allergic 
response. Allergen immunotherapy is highly effective and safe and confers long-
term clinical benefit in adequately selected patients. Furthermore, it is the only etio-
logical treatment for AR and asthma which conveys disease-modifying effect that 
can actually change the natural course of the disease [8, 9]. Thus, although LAR 
is by definition a local rather than systemic disease, few studies provide evidence 
for clinical benefit of allergen immunotherapy among LAR patients. These studies 
demonstrated a significant symptom improvement, an increase in the number of 
medication free days, and a beneficial effect on ocular symptoms, asthma control, 
and quality of life compared to placebo, as well as tolerance induction defined by an 
increase in allergen-specific IgG4 [6–8, 10].
8. Conclusions
In the last decade, growing evidence indicates that nasal reactivity to aeroal-
lergens can occur in the absence of evidence of systemic atopy. The published 
literature raised the suspicion that many patients diagnosed previously as suffering 
from non-allergic rhinitis actually suffer from LAR. This may be of importance as 
treatment options differ between non-allergic and AR/LAR diseases. Diagnosis of 
LAR remains a challenge, as none of the diagnostic methods suggested are opti-
mal nor commonly available in most centers. Therefore, high index of suspicion, 
utilizing specific methods if accessible as well as therapeutic challenge, may enable 
correct and early diagnosis. This may enable specific allergen-directed interven-
tions (e.g., allergen immunotherapy), as well as early detection and treatment of 
comorbidities (like asthma and conjunctivitis). In this regard, implementation of 
NAPT, BAT, and other methods of diagnosis, especially in referral centers, as well as 
long-term studies to better define the mechanisms, course, and response to therapy 
of LAR, is needed.
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